Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats

NeuroToxicology

Volumn 44, Issue , 2014, Pages 71-79

  Bisht, Rohit ^a   Kaur, Baninder ^a   Gupta, Hitu ^a   Prakash, Atish ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Ceftriaxone; MPTP; Neuroprotection; Oxidative damage; Ropinirole

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CATALASE; CEFTRIAXONE; CYTOKINE; DOPAMINE; GLUTAMATE TRANSPORTER; GLUTATHIONE; LIPOPOLYSACCHARIDE; NITRITE; ROPINIROLE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 1BETA; INDOLE DERIVATIVE; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEFENSE MECHANISM; DOPAMINERGIC SYSTEM; DOWN REGULATION; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; LOCOMOTION; MALE; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; ROTAROD TEST; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL MODEL; ANIMAL TISSUE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; CORPUS STRIATUM; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; GLUTAMATERGIC SYSTEM; NERVOUS SYSTEM INFLAMMATION; UPREGULATION; ANIMAL; DRUG EFFECTS; ENCEPHALITIS; METABOLISM; MOTOR ACTIVITY; MPTP POISONING; SUBSTANTIA NIGRA; WISTAR RAT;

RATTUS;

ANIMALS; CEFTRIAXONE; ENCEPHALITIS; INDOLES; MALE; MOTOR ACTIVITY; MPTP POISONING; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RATS; RATS, WISTAR; ROTAROD PERFORMANCE TEST; SUBSTANTIA NIGRA;

EID: 84904261643     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2014.05.009     Document Type: Article

References (55)

1. Bekris L.M., Mata I.F., Zabetian C.P. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 2010, 23:228-242.
2. Blanchet P.J., Calon F., Morissette M., et al. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat Disord 2004, 10:297-304.
3. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69.
4. Broen M., Duits A., Visser-Vandewalle V., Temel Y., Winogrodzka A. Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord 2011, 17:413-417.
5. Chu K., Lee S.T., Sinn D.I., et al. Pharmacological induction of ischemic tolerance by glutamate transporter-1 (EAAT2) upregulation. Stroke 2007, 38:177-182.
6. Chung E.K., Chen L.W., Chan Y.S., Yung K.K. Downregulation of glial glutamate transporters after dopamine denervation in the striatum of 6-hydroxydopamine-lesioned rats. J Comp Neurol 2008, 511:421-437.
7. Coldwell M.C., Boyfield I., Brown T., Hagan J.J., Middlemiss D.N. Comparison of the functional potencies of Ropinirolee and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1999, 127:1696-1702.
8. Cui C., Cui Y., Gao J., Sun L., Wang Y., Wang K., et al. Neuroprotective effect of ceftriaxone in a rat model of traumatic brain injury. Neurol Sci 2014, 35:695-700.
9. Danbolt N.C. Glutamate uptake. Prog Neurobiol 2001, 65:1-105.
10. Dawson T. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. PNAS 2010, 107:16691-16696.
11. Demel C., Hoegen T., Giese A., Angele B., Pfister H.W., Koedel U., et al. Reduced spiral ganglion neuronal loss by adjunctive neurotrophin-3 in experimental pneumococcal meningitis. J Neuroinflamm 2011, 8(1):7.
12. Duty S., Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 2011, 164:1357-1391.
13. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
14. Foran E., Trotti D. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid Redox Signal 2009, 11:1587-1602.
15. Fukuzaki K., Kamenosono T., Nagata R. Effects of Ropinirolee on various parkinsonian models in mice, rats, and cynomolgus monkeys. Pharmacol Biochem Behav 2000, 65:503-508.
16. Gornall A.G., Bardawill C.J., David M.M. Determination of serum proteins by means of the biuret reaction. J Biol Chem 1949, 177:751-766.
17. 15N) nitrate in biological fluids. J Biol Chem 1982, 193:265-275.
18. Greengard P., Allen P.B., Nairn A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 1999, 23:435-447.
19. Hassel B., Tessler S., Faull R.L., Emson P.C. Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem Res 2008, 33:232-237.
20. Inui T., Alessandri B., Heimann A., Nishimura F., Frauenknecht K., Sommer C., et al. Neuroprotective effect of ceftriaxone on the penumbra in a rat venous ischemia model. Neuroscience 2013, 242:1-10.
21. Kim K., Lee S.G., Kegelman T.P., et al. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol 2011, 226:2484-2493.
22. Klockgether T., Turski L. Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci 1989, 12:285-286.
23. Knackstedt L.A., Melendez R.I., Kalivas P.W. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biol Psychiatry 2010, 67:81-84.
24. Kulkarni S.K. Practical Pharmacology and Clinical Pharmacy 2008, 136-137. Vallabh Pub. 1st ed.
25. Kumar P., Kalonia H., Kumar A. Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats: protective effect of licofelone. Br J Pharmacol 2011, 164:644-654.
26. Kumar P., Kalonia H., Kumar A. Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity. Eur J Pharmacol 2012, 674:265-274.
27. Lee S.G., Su Z.Z., Emdad L., Gupta P., Sarkar D., Borjabad A., et al. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem 2008, 283:13116-13123.
28. Leung T.C., Lui C.N., Chen L.W., Yung W.H., Chan Y.S., Yung K. Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats. ACS Chem Neurosci 2012, 3:22-30.
29. Levy O.A., Malagelada C., Greene L.A. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis 2009, 14:478-500.
30. Li W., Zhao J.H., Sun S.G., Zhanq J.W., Suo A.Q., Ma M.M. Clinical rehabilitation effect of Ropinirole on cognitive and motor disorders in patients with Parkinson's disease. Zhonqhua Yi Xue Za Zhi 2011, 91:301-303.
31. Lipski J., Wan C.K., Bai J.Z., Pi R., Li D., Donnelly D. Neuroprotective potential of ceftriaxone in in vitro models of stroke. Neuroscience 2007, 146:617-629.
32. Luck H. Catalase. Methods of Enzymatic analysis 1971, vol. III:885-893. Academic Press, New York. 3rd ed.
33. Mccarty M.F. Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders. Med Hypotheses 2006, 67:251-269.
34. Moreau C., Delval A., Tiffreau V., et al. Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry 2013, 84:552-555.
35. Park G., Park Y.J., Yang H.O., Oh M.S. Ropinirole protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via anti-apoptotic mechanism. Pharmacol Biochem Behav 2013, 104:163-168.
36. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1986, Academic Press, London.
37. Pellegrino D., Cicchetti F., Wang X., Zhu A., Yu M., Saint-Pierre M., et al. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats. J Nucl Med 2007, 48:1147-1153.
38. Petroske E., Meredith G.E., Callen S., Totterdell S., Lau Y.S. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 2001, 106:589-601.
39. Pickering M., Cumiskey D., O'connor J.J. Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 2005, 90:663-670.
40. Plane J.M., Shen Y., Pleasure D.E., Deng W. Prospects for minocycline neuroprotection. Arch Neurol 2010, 67:1442-1448.
41. Purisai M.G., Mccormack A.L., Cumine S., Li J., Isla M.Z., Di Monte D.A. Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis 2007, 25:392-400.
42. Rao S.S., Hofmann L.A., Shakil A. Parkinson's disease: diagnosis and treatment. Am Fam Physician 2006, 74:2046-2054.
43. Rao V.L., Dogan A., Bowen K.K., Todd K.G., Dempsey R.J. Antisense knockdown of the glial glutamate transporter GLT-1 exacerbates hippocampal neuronal damage following traumatic injury to rat brain. Eur J Neurosci 2001, 13:119-128.
44. Rasmussen B.A., Baron D.A., Kim J.K., Unterwald E.M., Rawls S.M. Beta-lactam antibiotic produces a sustained reduction in extracellular glutamate in the nucleus accumbens of rats. Amino Acids 2011, 40:761-764.
45. Rawls S.M., Zielinski M., Patel H., Sacavage S., Baron D.A., Patel D. Beta-lactam antibiotic reduces morphine analgesic tolerance in rats through GLT-1 transporter activation. Drug Alcohol Depend 2010, 107:261-263.
46. Reksidler A.B., Lima M.M., Dombrowski P., Andersen M.L., Zanata S.M., Andreatini R., et al. Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease. J Neurosci Methods 2008, 167:268-277.
47. Rothstein J.D., Patel S., Regan M.R., et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
48. Seet R.C., Lee C.Y., Lim E.C., Tan J.J., Quek A.M., Chong W.L., et al. Oxidative damage in Parkinson disease: measurement using accurate biomarkers. Free Radic Biol Med 2010, 48:560-566.
49. Siegel S.J., Nagy L., Skarsfeldt T., et al. Ropinirole implants reverse MPTP-induced Parkinsonism in rhesus monkeys. Pharmacol Pharm 2013, 4:1-8.
50. Sheldon A.L., Robinson M.B. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int 2007, 51:333-355.
51. Siciliano G., Carlesi C., Pasquali L., Piazza S., Pietracupa S., Fornai F., et al. Clinical trials for neuroprotection in ALS. CNS Neurol Disord Drug Targets 2010, 9:305.
52. Singh A.K., Tiwari M.N., Dixit A., Upadhyay G., Patel D.K., Singh D., et al. Nigrostriatal proteomics of cypermethrin-induced dopaminergic neurodegeneration: microglial activation-dependent and -independent regulations. Toxicol Sci 2011, 122:526-538.
53. Veerendra Kumar M.H., Gupta Y.K. Intracerebroventricular administration of colchicine produces cognitive impairment associated with oxidative stress in rats. Pharmacol Biochem Behav 2002, 73:565-571.
54. Verma R., Mishra V., Sasmal D., Raghubir R. Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury. Eur J Pharmacol 2010, 638:65-71.
55. Wills E.D. Mechanism of lipid peroxide formation in animal tissues. Biochem J 1966, 99:667-676.